Please login to the form below

Not currently logged in
Email:
Password:

Histogenics names former MedImmune president as CEO

Peter Greenleaf to lead regenerative medicine company

Peter Greenleaf, HistogenicsPeter Greenleaf, the former president of AstraZeneca's (AZ) biologics arms MedImmune, has joined regenerative medicine company Histogenics as CEO.

Greenleaf was appointed president of MedImmune and related investment business MedImmune Ventures in February 2010, but three years later, he was one of several casualties in a shake-up of AZ's research efforts that also included the departure of president of R&D Martin Mackay.

Prior to serving as president, Greenleaf led the development of the MedImmune's global marketing and portfolio organisations and managed the broader commercial, corporate development and strategy functions.

Outside MedImmune, he has held several key leadership roles at Centocor, including VP of the US gastroenterology commercial group, as well as roles at Hallmark Cards, Boehringer Mannheim and US Healthcare.

In his new role, he will lead a company that specialises in combining cell therapy and tissue engineering technologies to develop products primarily for orthopaedic tissue repair.

This includes lead candidate NeoCart – a cartilage tissue implant in phase III trials.

“Peter's expertise in growing smaller biotech companies into industry leaders will be critical as we work to move NeoCart through pivotal trials and ultimately toward launch and commercialisation,” said Histogenics chairman Garheng Kong.

“While NeoCart will be the main focus in the near term, Peter will also help facilitate our vision for building out the company's platform technology and the future growth plans for the organisation.”

12th June 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics